Cited by 1,012Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCutaneous Melanoma Detection and Management

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

Open access

Attia, Peter, Phan, Giao Q., Maker, Ajay V., Robinson, Michael R., Quezado, Martha M., Yang, James C., Sherry, Richard M., Topalian, Suzanne L., Kammula, Udai S., Royal, Richard E., Restifo, Nicholas P., Haworth, Leah R., Levy, Catherine, Mavroukakis, Sharon A., Nichol, Geoff, Yellin, Michael J., Rosenberg, Steven A.·2005·Journal of Clinical Oncology

DOI 10.1200/jco.2005.06.205PMC PMC1473965

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: Previously, we reported our experience treating 14 patients with metastatic melanoma using a fully human antibody to cytotoxic T-lymphocyte antigen-4 (anti–CTLA-4) in conjunction with peptide vaccination. We have now treated 56 patients to evaluate two different dose schedules of anti–CTLA-4 and to explore the relationship between autoimmunity and tumor regression. Patients and Methods: A total of 56 patients with progressive stage IV melanoma were enrolled onto the study. All had Karnofsky performance status ≥ 60% with no prior history of autoimmunity. Twenty-nine patients received 3 mg/kg anti–CTLA-4 every 3 weeks, whereas 27 received 3 mg/kg as their initial dose with subsequent doses reduced to 1 mg/kg every 3 weeks. In both cohorts patients received concomitant vaccination with two modified HLA-A*0201-restricted peptides from the gp100 melanoma-associated antigen, gp100:209-217(210M) and gp100:280-288(288V). Results: Two patients achieved a complete response (ongoing at 30 and 31 months, respectively) and five patients achieved a partial response (durations of 4, 6, 25+, 26+, and 34+ months, respectively), for an overall objective response rate of 13%. Tumor regression was seen in lung, liver, brain, lymph nodes, and subcutaneous sites. Of 14 patients with grade 3/4 autoimmune toxicity, five (36%) experienced a clinical response compared with only two responses in the 42 patients (5%) with no autoimmune toxicity (P = .008). There were no significant differences in response rate or toxicity between the two dose schedules. Conclusion: Administration of anti–CTLA-4 monoclonal antibody plus peptide vaccination can cause durable objective responses, which correlate with the induction of autoimmunity, in patients with metastatic melanoma.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2005.06.205

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,090
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,860
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
CD4+CD25+ suppressor T cells: more questions than answers
Shevach, E. M. (2002) · Nature reviews. Immunology · doi:10.1038/nri821 · Cited by 2,097

Show all 44 references

Sorted by citations

Items 301–400 of 1,000

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials
Kanjanapan, Y., Day, D., Butler, M. O., Wang, L., Joshua, A. M., Hogg, D., Leighl, N. B., Razak, A. R. A., Hansen, A. R., Boujos, S., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.017 · Cited by 72
Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma
Mochel, M. C., Ming, M. E., Imadojemu, S. E., Gangadhar, T. C., Schuchter, L. M., Elenitsas, R., Payne, A. S., & Chu, E. Y. (2016) · Journal of Cutaneous Pathology · doi:10.1111/cup.12735 · Cited by 72
Metabolic checkpoints in immune cell reprogramming: rewiring immunometabolism for cancer therapy
Lv, Y., Li, Z., Liu, S., Zhou, Z., Jinling, S., Ba, Y., Weng, S., Zuo, A., Xu, H. W., Luo, P., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02407-6 · Cited by 93
CTLA-4 blockade and the renaissance of cancer immunotherapy
D, S. M. M., & Nitti, D. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.05.003 · Cited by 72
Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells
Khan, S. S., Burt, D. J., Ralph, C., Thistlethwaite, F. C., Hawkins, R. E., & Elkord, E. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.09.011 · Cited by 72
From T‐cell activation signals to signaling control of anti‐cancer immunity
Cronin, S. J. F., & Penninger, J. M. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00570.x · Cited by 73
Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer
Minnar, C. M., Sckisel, G. D., Proia, D. A., Mirsoian, A., Grossenbacher, S. K., Pai, C.-C. S., Chen, M., Monjazeb, A. M., Kelly, K. L., Blazar, B. R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1075114 · Cited by 73
Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition
Chat, V., Ferguson, R., Simpson, D., Kazlow, E., Lax, R., Moran, U., Pavlick, A. C., Frederick, D. T., Boland, G. M., Sullivan, R. J., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02318-8 · Cited by 70
RETINAL TOXICITIES OF CANCER THERAPY DRUGS
Liu, C. Y., Francis, J. H., Brodie, S. E., Marr, B. P., Pulido, J. S., Marmor, M. F., & Abramson, D. H. (2014) · Retina · doi:10.1097/iae.0000000000000242 · Cited by 69
Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity
Inno, A., Metro, G., Bironzo, P., Grimaldi, A. M., Grego, E., Nunno, V. D., Picasso, V., Massari, F., & Gori, S. (2017) · Tumori Journal · doi:10.5301/tj.5000625 · Cited by 70
Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach
Iglesias, P. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.08.019 · Cited by 70
History and current state of immunotherapy in glioma and brain metastasis
McGranahan, T. M., Li, G., & Nagpal, S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017693750 · Cited by 73
Hyponatremia associated with Ipilimumab-induced hypophysitis
Barnard, Z. R., Walcott, B. P., Kahle, K. T., Nahed, B. V., & Coumans, J. V. (2011) · Medical Oncology · doi:10.1007/s12032-010-9794-7 · Cited by 68
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
Karaki, S., Anson, M., Tran, T., Giusti, D., Blanc, C., Oudard, S. M., & Tartour, É. (2016) · Vaccines · doi:10.3390/vaccines4040037 · Cited by 73
Iatrogenic pathology of the intestines
McCarthy, A. J., Lauwers, G. Y., & Sheahan, K. D. (2015) · Histopathology · doi:10.1111/his.12598 · Cited by 66
Early Administration of Infliximab for Severe Ipilimumab-Related Diarrhea in a Critically Ill Patient
Merrill, S. P., Reynolds, P., Kalra, A., Biehl, J., Vandivier, R. W., & Mueller, S. W. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014528152 · Cited by 66
Partial Reduction of Human FOXP3+ CD4 T Cells In Vivo After CD25-directed Recombinant Immunotoxin Administration
Powell, D. J., Attia, P., Ghetie, V. F., Schindler, J. D., Vitetta, E. S., & Rosenberg, S. A. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31815dc0e8 · Cited by 66
Self-citation
Treatment of cutaneous melanoma: current approaches and future prospects
DAUD, A. I., Algazi, A., & Soon, C. (2010) · Cancer Management and Research · doi:10.2147/cmar.s6073 · Cited by 66
Prognostic score for patients with advanced melanoma treated with ipilimumab
Diem, S., Kasenda, B., Martín-Liberal, J., Lee, A. T. J., Chauhan, D., Gore, M. E., & Larkin, J. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.09.007 · Cited by 66
Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment
Wang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66
Recent developments in the medical and surgical treatment of melanoma
Saranga‐Perry, V., Ambe, C. M., Zager, J. S., & Kudchadkar, R. R. (2014) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21224 · Cited by 65
18F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis
Perng, P., Marcus, C. V., & Subramaniam, R. M. (2015) · American Journal of Roentgenology · doi:10.2214/ajr.14.13575 · Cited by 67
Combating Immunosuppression in Glioma
Vega, E. A., Graner, M. W., & Sampson, J. H. (2008) · Future Oncology · doi:10.2217/14796694.4.3.433 · Cited by 64
Naturally-existing CD4+CD25+Foxp3+ regulatory T cells are required for tolerance to experimental autoimmune thyroiditis induced by either exogenous or endogenous autoantigen
Morris, G. P., Brown, N. K., & Kong, Y.-C. M. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.03.010 · Cited by 65
Therapeutic vaccines in solid tumours: Can they be harmful?
Eggermont, A. M. M. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.05.004 · Cited by 65
CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent
Gattinoni, L., Ranganathan, A., Surman, D. R., Palmer, D. C., Antony, P. A., Theoret, M. R., Heimann, D. M., Rosenberg, S. A., & Restifo, N. P. (2006) · Blood · doi:10.1182/blood-2006-07-034066 · Cited by 65
Self-citation
Diverse Mechanisms Regulate the Surface Expression of Immunotherapeutic Target CTLA-4
Schneider, H., & Rudd, C. E. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00619 · Cited by 65
Clinical characterization of colitis arising from anti-PD-1 based therapy
Wang, D. Y., Mooradian, M. J., Kim, D. W., Shah, N. J., Fenton, S. E., Conry, R. M., Mehta, R. J., Silk, A. W., Zhou, A. Y., Compton, M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1524695 · Cited by 66
Targeting Immune Checkpoints
Postow, M. A., Harding, J. J., & Wolchok, J. D. (2012) · The Cancer Journal · doi:10.1097/01.ppo.0000581876.62921.87 · Cited by 64
Adenovirus Expressing Both Thymidine Kinase and Soluble PD1 Enhances Antitumor Immunity by Strengthening CD8 T-cell Response
Shin, S.-P., Seo, H.-H., Shin, J.-H., Park, H.-B., Lim, D. P., Eom, H., Bae, Y., Kim, I.-H., Choi, K., & Lee, S.-J. (2013) · Molecular Therapy · doi:10.1038/mt.2012.252 · Cited by 63
The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?
Newsome, B. W., & Ernstoff, M. S. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03187.x · Cited by 63
A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients
Cortellini, A., Buti, S., Agostinelli, V., & Bersanelli, M. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.10.003 · Cited by 62
A Viral Vaccine Encoding Prostate-Specific Antigen Induces Antigen Spreading to a Common Set of Self-Proteins in Prostate Cancer Patients
Nesslinger, N. J., Ng, A. V., Tsang, K.-Y., Ferrara, T. A., Schlom, J., Gulley, J. L., & Nelson, B. H. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0948 · Cited by 62
New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors
Ciccarese, C., Alfieri, S., Santoni, M., Santini, D., Brunelli, M., Bergamini, C., Licitra, L. F., Montironi, R., Tortora, G., & Massari, F. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1120287 · Cited by 62
Cytotoxic T-Lymphocyte–Associated Antigen-4
Hodi, F. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0813 · Cited by 63
Immunomodulatory therapy for melanoma: Ipilimumab and beyond
Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2013) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2012.08.006 · Cited by 63
The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience
Berman, D., Korman, A. J., Peck, R., Feltquate, D., Lönberg, N., & Canetta, R. M. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.017 · Cited by 65
British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis
Powell, N., Ibraheim, H., Raine, T., Speight, A., Papa, S., Brain, O., Green, M., Samaan, M., Spain, L. A., Yousaf, N., et al. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30014-5 · Cited by 63
Immunosuppressive mechanisms in human tumors: Why we still cannot cure cancer
Groß, S., & Walden, P. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.11.012 · Cited by 60
Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy
Tissot, C., Carsin, A., Freymond, N., Pachéco, Y., & Devouassoux, G. (2012) · European Respiratory Journal · doi:10.1183/09031936.00107912 · Cited by 60
Neoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis
Touhami, S., Audo, I. S., Terrada, C., Gaudric, A., LeHoang, P., Touitou, V., & Bodaghi, B. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.05.002 · Cited by 60
Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model
Hinterleitner, R., Gruber, T., Pfeifhofer-Obermair, C., Lutz-Nicoladoni, C., Tzankov, A., Schuster, M., Penninger, J. M., Loibner, H., Lametschwandtner, G., Wolf, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044295 · Cited by 59
Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis
Bostwick, A. D., Salama, A. K. S., & Hanks, B. A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0064-2 · Cited by 59
Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer
Vella, L. A., Yu, M., Fuhrmann, S. R., El-Amine, M., Epperson, D. E., & Finn, O. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903225106 · Cited by 59
Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab
Damuzzo, V., Solito, S., Pinton, L., Carrozzo, E., Valpione, S., Pigozzo, J., Arboretti, R., Chiarion‐Sileni, V., & Mandruzzato, S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1249559 · Cited by 60
Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome
Mirza, S., Hill, E., Ludlow, S. P., & Nanjappa, S. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000326 · Cited by 58
p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression
Lu, Y., Zhang, M., Wang, S., Hong, B., Wang, Z., Li, H., Zheng, Y., Yang, J., Davis, R. E., Qian, J., et al. (2014) · Nature Communications · doi:10.1038/ncomms5229 · Cited by 58
Self-citation
CTLA-4 Blockade with Monoclonal Antibodies in Patients with Metastatic Cancer: Surgical Issues
Phan, G. Q., Weber, J. S., & Sondak, V. K. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0104-y · Cited by 58
Self-citation
Immune Checkpoint Inhibitor Therapy Associated Hypophysitis
Mahzari, M. M., Liu, D., Arnaout, A., & Lochnan, H. A. (2015) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s22469 · Cited by 58
Immunotherapy as a strategy for the treatment of non-small-cell lung cancer
Holt, G. E., Podack, E. R., & Raez, L. E. (2010) · Therapy · doi:10.2217/thy.10.84 · Cited by 57
Immunotherapy of distant metastatic disease
Schadendorf, D., Martín‐Algarra, S., Bastholt, L., Cinat, G., Dréno, B., Eggermont, A. M. M., Espinosa, E., Guo, J., Hauschild, A., Petrella, T. M., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp253 · Cited by 58
CTLA-4 Blockade following Relapse of Malignancy after Allogeneic Stem Cell Transplantation Is Associated with T Cell Activation But Not with Increased Levels of T Regulatory Cells
Zhou, J., Bashey, A., Zhong, R., Corringham, S., Messer, K. S., Pu, M., Ma, W., Chut, T., Soiffer, R. J., Mitrovich, R., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.08.005 · Cited by 58
Use of LDH and Autoimmune Side Effects to Predict Response to Ipilimumab Treatment
Dick, J., Lang, N., Slynko, A., Kopp‐Schneider, A., Schulz, C., Dimitrakopoulou‐Strauss, A., Enk, A. H., & Hassel, J. (2016) · Immunotherapy · doi:10.2217/imt-2016-0083 · Cited by 58
Recent Advances Using Anti-CTLA-4 for the Treatment of Melanoma
Sarnaik, A. A., & Weber, J. S. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181a7450f · Cited by 60
Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages
Dong, H., Li, M., Yang, C., Wei, W., He, X., Cheng, G., & Wang, S. (2023) · Cancer Cell International · doi:10.1186/s12935-022-02846-x · Cited by 57
Personalized approaches to active immunotherapy in cancer
Ophir, E., Bobisse, S., Coukos, G., Harari, A., & Kandalaft, L. E. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.07.004 · Cited by 57
Immunotherapy in Non–Small Cell Lung Cancer Treatment
Carter, B. W., Halpenny, D. F., Ginsberg, M. S., Papadimitrakopoulou, V. A., & de Groot, P. M. (2017) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000291 · Cited by 57
Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity
Simmons, A. D., Москаленко, М., Creson, J. R., Fang, J., Yi, S., VanRoey, M. J., Allison, J. P., & Jooss, K. U. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0451-3 · Cited by 58
+49G > A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population
Gu, X., Qi, P., Zhou, F., Ji, Q., Wang, H., Dou, T., Zhao, Y., & Gao, C. (2009) · Human Immunology · doi:10.1016/j.humimm.2009.09.353 · Cited by 56
Novel Treatments for Metastatic Cutaneous Melanoma and the Management of Emergent Toxicities
Lemech, C., & Arkenau, H. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s5855 · Cited by 56
Ipilimumab in advanced melanoma
Farolfi, A., Ridolfi, L., Guidoboni, M., Nicoletti, S. V. L., Piciucchi, S., Valmorri, L., Costantini, M., Scarpi, E., Amadori, D., & Ridolfi, R. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e328353e65c · Cited by 56
Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution
Guaraldi, F., Selva, R. L., Samà, M. T., D’Angelo, V., Gori, D., Fava, P., Fierro, M. T., Savoia, P., & Arvat, E. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0772-1 · Cited by 56
Practical Management of Immune-Related Adverse Events from Immune Checkpoint Protein Antibodies for the Oncologist
Weber, J. S. (2012) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2012.32.79 · Cited by 57
Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy
Lizee, G. A., Cantu, M. A., & Hwu, P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1722 · Cited by 59
Systemic therapy for metastatic malignant melanoma – from deeply disappointing to bright future?
Lorigan, P. C., Eisen, T. G., & Hauschild, A. (2008) · Experimental Dermatology · doi:10.1111/j.1600-0625.2007.00673.x · Cited by 53
Enhancing cancer vaccines with immunomodulators
Berinstein, N. L. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.06.043 · Cited by 55
Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease
Phadke, S. D., Ghabour, R., Swick, B. L., Swenson, A., Milhem, M. M., & Zakharia, Y. (2016) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709616674316 · Cited by 54
Optimising anti‐tumour CD8 T‐cell responses using combinations of immunomodulatory antibodies
Gray, J. C., French, R. R., James, S., Al‐Shamkhani, A., Johnson, P., & Glennie, M. J. (2008) · European Journal of Immunology · doi:10.1002/eji.200838208 · Cited by 54
A Neuropilin-1 Antagonist Exerts Antitumor Immunity by Inhibiting the Suppressive Function of Intratumoral Regulatory T Cells
Jung, K., Kim, J.-A., Kim, Y.-J., Lee, H. W., Kim, C.-H., Haam, S., & Kim, Y.-S. (2019) · Cancer immunology research · doi:10.1158/2326-6066.cir-19-0143 · Cited by 49
Immunotherapy of melanoma: a critical review of current concepts and future strategies
Riker, A. I., Radfar, S., Liu, S., Wang, Y., & Khong, H. T. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.3.345 · Cited by 53
Roadmap to a Better Therapeutic Tumor Vaccine
Emens, L. A. (2006) · International Reviews of Immunology · doi:10.1080/08830180600992423 · Cited by 53
Autoimmunity and treatment outcome in melanoma
Bouwhuis, M. G., ten Hagen, T. L. M., Suciu, S., & Eggermont, A. M. M. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328341edff · Cited by 54
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm
Khattak, M. A., Fisher, R. A., Turajlic, S., & Larkin, J. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012466280 · Cited by 53
The Impact of Immune Checkpoint Inhibitor-Related Adverse Events and Their Immunosuppressive Treatment on Patients’ Outcomes
Abu‐Sbeih, H., Tang, T., Ali, F. S., Johnson, D. H., Qiao, W., Diab, A. K., & Wang, Y. (2018) · Journal of Immunotherapy and Precision Oncology · doi:10.4103/jipo.jipo_12_18 · Cited by 53
Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab
Giannicola, R., D’Arrigo, G., Botta, C., Agostino, R. M., Medico, P. D., Falzea, A. C., Barbieri, V., Staropoli, N., Giudice, T. D., Pastina, P., et al. (2019) · Molecular and Clinical Oncology · doi:10.3892/mco.2019.1859 · Cited by 53
Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis
Abdelrahim, M., Mamlouk, O., Lin, H. Y., Lin, J. S., Page, V. D., Abdel‐Wahab, N., Swan, J. T., Selamet, U., Yee, C., Diab, A. K., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1927313 · Cited by 51
Anti-CTLA4 antibody clinical trials in melanoma
Ribas, A. (2007) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2007.09.001 · Cited by 51
Novel immunotherapies for hematologic malignancies
Nelson, M. H., & Paulos, C. M. (2014) · Immunological Reviews · doi:10.1111/imr.12245 · Cited by 52
Advances in systemic treatment of melanoma
Eggermont, A. M. M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq364 · Cited by 52
Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma
Bernardo, S. G., Москаленко, М., Pan, M. M., Shah, S. D., Sidhu, H. K., Sicular, S., Harcharik, S., Chang, R. R., Friedlander, P. A., & Saenger, Y. M. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e32835c7e68 · Cited by 51
Toxicity as a result of immunostimulation by biologics
Gribble, E. J., Sivakumar, P. V., Ponce, R. A., & Hughes, S. D. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.2.209 · Cited by 51
Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer
Howell, M., Lee, R. J., Bowyer, S. E., Fusi, A., & Lorigan, P. C. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.02.007 · Cited by 51
18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab
Sachpekidis, C., Kopp‐Schneider, A., Hakim-Meibodi, L. E., Dimitrakopoulou‐Strauss, A., & Hassel, J. C. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000541 · Cited by 50
Targeting tumor-resident mast cells for effective anti-melanoma immune responses
Kaesler, S., Wölbing, F., Kempf, W. E., Skabytska, Y., Köberle, M., Volz, T., Sinnberg, T. W., Amaral, T. M. S., Möckel, S. M. C., Yazdi, A. S., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.125057 · Cited by 51
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
Correale, P., Saladino, R. E., Giannarelli, D., Sergi, A., Mazzei, M. A., Bianco, G., Giannicola, R., Iuliano, E., Forte, I. M., Calandruccio, N. D., et al. (2020) · Cells · doi:10.3390/cells9091964 · Cited by 50
Systemic cancer therapy: Evolution over the last 60 years
Dy, G. K., & Adjei, A. A. (2008) · Cancer · doi:10.1002/cncr.23651 · Cited by 52
Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma
Lindsey, K. R., Gritz, L. R., Sherry, R. M., Abati, A. D., Fetsch, P. A., Goldfeder, L. C., Gonzales, M. I., Zinnack, K., Rogers-Freezer, L. J., Haworth, L. R., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2061 · Cited by 50
Self-citation
Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?
Sachpekidis, C., Larribère, L., Kopp‐Schneider, A., Hassel, J. C., & Dimitrakopoulou‐Strauss, A. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2279-9 · Cited by 49
Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles
Ye, W., Olsson-Brown, A. C., Watson, R. A., Cheung, V., Morgan, R. D., Nassiri, I., Cooper, R. A., Taylor, C. A., Akbani, U., Brain, O., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01310-3 · Cited by 49
Anti–Cytotoxic T-Cell Lymphocyte Antigen-4–Induced Regression of Spinal Cord Metastases in Association With Renal Failure, Atypical Pneumonia, Vision Loss, and Hearing Loss
Voskens, C., Cavallaro, A., Erdmann, M., Dippel, O., Kaempgen, E., Schuler, G., Schuler‐Thurner, B., & Heinzerling, L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4359 · Cited by 49
Melanoma-Associated Retinopathy Treated with Ipilimumab Therapy
Audemard‐Verger, A., de Raucourt, S., Miocque, S., Comoz, F., Giraud, J. M., Dréno, B., Bienvenu, B. J., Rogerie, M.-J., & Dompmartin, A. (2013) · Dermatology · doi:10.1159/000353408 · Cited by 49
Mechanisms of checkpoint inhibition-induced adverse events
Urwyler, P., Earnshaw, I., Bermudez, M., Perucha, E., Wu, W., Ryan, S. E., Mcdonald, L., Karagiannis, S. N., Taams, L. S., Powell, N., et al. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13421 · Cited by 48
Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis
Zhao, Z., Wang, X., Qu, J., Zuo, W., Tang, Y., Zhu, H., & Chen, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.708195 · Cited by 49
Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment
Liu, Y., Geng, Y., Yue, B., Lo, P., Huang, J., & Jin, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.832942 · Cited by 50
Treating Cancer by Targeting the Immune System
Hwu, P. (2010) · New England Journal of Medicine · doi:10.1056/nejme1006416 · Cited by 49
Myosite orbitaire associée à un traitement par ipilimumab
Lecouflet, M., Verschoore, M., Giard, C., Gohier, P., Corre, Y. L., Miléa, D., & Martin, L. (2013) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2013.02.029 · Cited by 48
Melanoma and Immunotherapy
Eggermont, A. M. M., & Schadendorf, D. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.03.009 · Cited by 48
Update on the diagnosis and management of hypophysitis
Carmichael, J. D. (2012) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32835430ed · Cited by 48
Ipilimumab-induced colitis in patients with metastatic melanoma
Felice, K. M. D., Gupta, A., Rakshit, S., Khanna, S., Kottschade, L. A., Finnes, H. D., Papadakis, K. A., Loftus, E. V., Raffals, L. E., & Markovic, S. N. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000165 · Cited by 48
18F-FDG PET/CT Can Predict Development of Thyroiditis Due to Immunotherapy for Lung Cancer
Eshghi, N., Garland, L. L., Nia, E. S., Betancourt, R., Krupinski, E. A., & Kuo, P. H. (2018) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.117.204933 · Cited by 48

Authors: Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Restifo, N. P., Haworth, L. R., Levy, C., Mavroukakis, S. A., Nichol, G., Yellin, M. J., & Rosenberg, S. A.
Affiliations: National Institutes of Health (US)
ORCID: Phan, Giao Q.
Maker, Ajay V.
Robinson, Michael R.
Quezado, Martha M.
Yang, James C.
Sherry, Richard M.
Topalian, Suzanne L.
Kammula, Udai S.
Restifo, Nicholas P.
Mavroukakis, Sharon A.
Yellin, Michael J.
Rosenberg, Steven A.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2005-09-01
Volume: 23
Issue: 25
Pages: 6043-6053
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2005.06.205
PMC: PMC1473965
OpenAlex: W2151507811
Cited by: 1,012
References: 44
Citations by year: 2026: 6 · 2025: 15 · 2024: 18 · 2023: 17 · 2022: 31 · 2021: 45 · 2020: 81 · 2019: 46 · 2018: 45 · 2017: 55 · 2016: 60 · 2015: 64 · 2014: 49 · 2013: 63 · 2012: 43
FWCI: 30.93
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (Z99 CA999999)
National Cancer Institute (Z01BC010763)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords: metastatic melanoma, anti-CTLA-4 monoclonal antibody, CTLA-4 blockade, autoimmunity, autoimmune toxicity, tumor regression, peptide vaccination, gp100, dosing regimen, immune checkpoint inhibitors, objective response rate
MeSH terms: Adult, Aged, Antigens, Differentiation, Drug Administration Schedule, Female, Humans, Immunosuppressive Agents, Injections, Intravenous, Male, Melanoma, Middle Aged, Prognosis, Skin Neoplasms, Autoimmunity, Antigens, CD, Treatment Outcome, Cancer Vaccines, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks